Epitope-Driven Polyfunctional Divergence of SARS-CoV-2 RBD Antibodies
Authors:
Preprint
Abstract
SUMMARY: SARS-CoV-2 antibodies targeting the receptor binding domain (RBD) of the spike protein can potently neutralize infection and exert additional antiviral functions. Here, we characterize the functional profiles of human RBD-specific memory B-cell antibodies elicited by ancestral SARS-CoV-2 infection. While SARS-CoV2 neutralizing antibodies, mainly class 1 and 3 anti-RBD antibodies, often lose binding and neutralizing capacities against Omicron variants, most non-neutralizers remain broadly reactive. Despite their restricted cross-reactivity, neutralizing antibodies mediate Fc-effector functions including antibody-dependent cellular cytotoxicity, phagocytosis, and complement deposition. Most neutralizers also enhance binding of antibodies that target the SARS-CoV-2 spike fusion peptide via receptor-mimetic allostery. In contrast, broadly reactive non-neutralizers fail to trigger phagocytic or allosteric effects. Thus, viral escape compromises antibody neutralizing as well as other antiviral activities, leaving broadly reactive, non-polyfunctional antibodies that exert minimal immune pressure less effective at controlling infection.Keywords
This publication has 73 references indexed in Scilit:
- Protective effect and molecular mechanisms of human non-neutralizing cross-reactive spike antibodies elicited by SARS-CoV-2 mRNA vaccinationCell Reports, 2024
- A potent pan-sarbecovirus neutralizing antibody resilient to epitope diversificationCell, 2024
- Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariantsCell, 2022
- Rational identification of potent and broad sarbecovirus-neutralizing antibody cocktails from SARS convalescentsCell Reports, 2022
- LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variantsCell Reports, 2022
- Tackling COVID-19 with neutralizing monoclonal antibodiesCell, 2021
- Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protectionCell, 2021
- Compromised Humoral Functional Evolution Tracks with SARS-CoV-2 MortalityCell, 2020
- Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution SerologyCell, 2020
- Scarcity of autoreactive human blood IgA+ memory B cellsEuropean Journal of Immunology, 2016